Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions
- PMID: 20856693
- PMCID: PMC2941213
- DOI: 10.2217/fnl.10.31
Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions
Abstract
With Alzheimer's disease increasing in prevalence and public awareness, more people are becoming interested in learning their chances of developing this condition. Disclosing Alzheimer's disease risk has been discouraged because of the limited predictive value of available tests, lack of prevention and treatment options, and concerns regarding potential psychological and social harms. However, challenges to this status quo include the availability of direct-to-consumer health risk information (e.g., genetic susceptibility tests), as well as a growing literature suggesting that people seeking risk information for Alzheimer's disease through formal education and counseling protocols generally find it useful and do not experience adverse effects. This paper reviews current and potential methods of risk assessment for Alzheimer's disease, discusses the process and impact of disclosing risk to interested patients and consumers, and considers the practical and ethical challenges in this emerging area. Anticipated future directions are addressed.
Conflict of interest statement
This work was supported by grants from the NIH (HG02213) and the Alzheimer’s Association (IIRG-07–58189). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
The authors thank Lindsay Zausmer for her assistance with manuscript preparation.
Similar articles
-
Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172. PMID: 28876770 Free Books & Documents. Review.
-
The ethics of disclosing genetic diagnosis for Alzheimer's disease: do we need a new paradigm?Br Med Bull. 2011;100:7-21. doi: 10.1093/bmb/ldr023. Epub 2011 Jun 14. Br Med Bull. 2011. PMID: 21672937 Review.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.Prog Neurobiol. 2013 Nov;110:89-101. doi: 10.1016/j.pneurobio.2013.02.005. Epub 2013 Apr 9. Prog Neurobiol. 2013. PMID: 23583530 Free PMC article. Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
Cited by
-
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.Neurodegener Dis Manag. 2013;3(3):219-229. doi: 10.2217/nmt.13.25. Neurodegener Dis Manag. 2013. PMID: 26167204 Free PMC article.
-
Kinetics and Molecular Docking Studies of 6-Formyl Umbelliferone Isolated from Angelica decursiva as an Inhibitor of Cholinesterase and BACE1.Molecules. 2017 Sep 24;22(10):1604. doi: 10.3390/molecules22101604. Molecules. 2017. PMID: 28946641 Free PMC article.
-
A mixed-methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexican-Americans at-risk for autosomal dominant Alzheimer's disease.J Genet Couns. 2019 Oct;28(5):921-932. doi: 10.1002/jgc4.1133. Epub 2019 Jun 17. J Genet Couns. 2019. PMID: 31207006 Free PMC article.
-
Normal-But-Low Serum Folate Levels and the Risks for Cognitive Impairment.Psychiatry Investig. 2019 Jul;16(7):532-538. doi: 10.30773/pi.2019.05.29. Epub 2019 Jul 25. Psychiatry Investig. 2019. PMID: 31352735 Free PMC article.
-
From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting.Alzheimers Dement (N Y). 2018 May 24;4:243-251. doi: 10.1016/j.trci.2018.04.002. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 29955667 Free PMC article. Review.
References
Bibliography
-
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–191. - PubMed
-
-
Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2009;5(3):234–270.. ▪▪ A public health review of epidemiologic statistics, disease impact on caregiving and healthcare costs, and advances in risk factor knowledge, diagnosis and treatment for Alzheimer’s disease (AD) and mild cognitive impairment.
-
-
- Neumann PJ, Hammitt JK, Mueller C, et al. Public attitudes about genetic testing for Alzheimer’s disease. Health Aff. (Millwood) 2001;20(5):252–264. - PubMed
-
- Morris JC. Dementia Update 2005. Alzheimer Dis. Assoc. Disord. 2005;19(2):100–117. - PubMed
-
- Offit K. Genomic profiles for disease risk: predictive or premature? JAMA. 2008;299(11):1353–1355. - PubMed
Websites
-
- Alzheimer’s Association. Maintain your brain. www.alz.org/we_can_help_brain_health_maintain_your_brain.asp.
-
- Siteman Cancer Center. Your disease risk. 2007. www.yourdiseaserisk.wustl.edu.
-
- National Cancer Institute. Breast Cancer Risk Assessment Tool. www.cancer.gov/bcrisktool.
-
- Sipkoff M. Alzheimer’s drug pipeline is robust, and usage is quickly expanding. Managed Care Magazine. 2009. www.managedcaremag.com/archives/0906/0906.alzheimers.html. - PubMed
-
- Direct-to-consumer genetic testing companies: Genetics and Public Policy Center. 2009. www.dnapolicy.org/resources/DTCcompanieslist.pdf.
Patent
-
- US5508167. 1996.
Grants and funding
LinkOut - more resources
Full Text Sources